Research programme: NOX inhibitors - GenKyoTex

Drug Profile

Research programme: NOX inhibitors - GenKyoTex

Alternative Names: GKT-03; GKT-136901; GKT-771; GKT-901; HTS programme; NOX inhibitors - GenKyoTex

Latest Information Update: 30 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GenKyoTex
  • Class Analgesics; Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action NOX1 protein inhibitors; NOX4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Inflammation; Pain
  • Research Cancer; Hearing loss; Parkinson's disease
  • Discontinued Diabetic nephropathies; Idiopathic pulmonary fibrosis

Most Recent Events

  • 25 Jul 2018 Research programme: NADPH oxidase inhibitors - GenKyoTex is available for licensing as of 25 Jul 2018.
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Switzerland
  • 26 Oct 2017 Preclinical development in Cardiovascular disorders is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top